Pictet Asset Management Holding SA Has $25.40 Million Stock Position in CVS Health Co. (NYSE:CVS)

Pictet Asset Management Holding SA decreased its stake in shares of CVS Health Co. (NYSE:CVS - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 565,896 shares of the pharmacy operator's stock after selling 9,319 shares during the period. Pictet Asset Management Holding SA's holdings in CVS Health were worth $25,403,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new position in CVS Health during the fourth quarter worth about $839,574,000. Davis Selected Advisers lifted its stake in CVS Health by 2,998.1% during the fourth quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator's stock valued at $511,115,000 after purchasing an additional 11,018,438 shares during the last quarter. Pzena Investment Management LLC boosted its holdings in CVS Health by 49.3% during the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock worth $880,319,000 after buying an additional 6,475,271 shares in the last quarter. Hotchkis & Wiley Capital Management LLC increased its holdings in shares of CVS Health by 34.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 11,897,034 shares of the pharmacy operator's stock valued at $748,085,000 after buying an additional 3,071,613 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of CVS Health during the 4th quarter valued at $116,033,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Down 5.9 %

CVS stock traded down $3.97 during trading hours on Friday, hitting $63.54. The company's stock had a trading volume of 13,291,234 shares, compared to its average volume of 11,586,970. The company has a market capitalization of $80.11 billion, a PE ratio of 17.36, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. The stock has a 50 day moving average price of $63.47 and a two-hundred day moving average price of $58.01. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $74.85.

Remove Ads

CVS Health (NYSE:CVS - Get Free Report) last posted its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. On average, equities research analysts expect that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be issued a $0.665 dividend. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a yield of 4.19%. CVS Health's dividend payout ratio (DPR) is presently 72.68%.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of recent analyst reports. StockNews.com raised CVS Health from a "sell" rating to a "hold" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. upped their price objective on shares of CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a research note on Tuesday, February 18th. UBS Group dropped their target price on shares of CVS Health from $62.00 to $59.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 11th. Wells Fargo & Company upped their price target on shares of CVS Health from $68.00 to $73.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Finally, Wolfe Research boosted their target price on shares of CVS Health from 67.00 to 70.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, CVS Health presently has an average rating of "Moderate Buy" and an average target price of $70.39.

Insiders Place Their Bets

In other CVS Health news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares of the company's stock, valued at $556,941.90. The trade was a 47.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael F. Mahoney acquired 30,000 shares of CVS Health stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the transaction, the director now directly owns 39,356 shares of the company's stock, valued at $2,625,045.20. This trade represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.24% of the company's stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.